Why Is Protara Therapeutics Stock Skyrocketing Over 100% On Thursday?

On Thursday, Protara Therapeutics Inc. (NASDAQ:TARA) stock traded higher after the company revealed results from its ongoing Phase 2 open-label ADVANCED-2 trial.

The trial is assessing intravesical TARA-002, the company’s investigational cell-based therapy, in high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) patients with carcinoma in situ or CIS (± Ta/T1) who are Bacillus Calmette-Guérin (BCG)-Unresponsive or BCG-Naïve.

Also Read: Protara Therapeutics Shares Interim Data From Bladder Cancer Study, Raises $45M Via Equity

The complete response (CR) rate across BCG exposures was ...

Full story available on Benzinga.com